CVRx, Inc., a privately held medical device company, has closed on an additional $12 million under its Series F financing. This brings the total raised in the Series F financing to $42 million.
CVRx plans to use the funding for the primary purposes of advancing its clinical trials and expanding its international commercial activities. New investors added in this round of financing included Ysios Capital, DaVita HealthCare Partners Inc. and others. In conjunction with this transaction, Josep Sanfeliu, General Partner of Ysios Capital, joined the CVRx Board of Directors.
"CVRx is recognized as a strong, innovative leader," said Sanfeliu. "I am excited to join the Board of Directors as a European active medtech investor and look forward to working with the CVRx team to build upon their clinical and commercial success."